For patients with COVID-19, selective serotonin reuptake inhibitors (SSRIs) are associated with a reduced relative risk for mortality, according to a study published online Nov. 15 in JAMA Network Open.
A large analysis of health records from 87 health care centers across the United States found that people taking a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs)...